Kaletra

Hepatitis C, Chronic, Hepatitis C, Chronic, Obesity + 3 more

Treatment

1 FDA approval

20 Active Studies for Kaletra

What is Kaletra

Ritonavir

The Generic name of this drug

Treatment Summary

Ritonavir is a medication used to treat HIV by blocking the virus from reproducing. It is usually given in combination with other protease inhibitors, such as Technivie, Holkira Pak, and Viekira Pak. It is also used to treat chronic hepatitis C genotypes 1a and 1b, either with or without cirrhosis, in combination with Ribavirin. Ritonavir can increase the effectiveness of other protease inhibitors and should not be used in combination with HIV-1 protease inhibitor treatments as it can lead to drug resistance.

Kaletra

is the brand name

image of different drug pills on a surface

Kaletra Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kaletra

Ritonavir

2000

50

Approved as Treatment by the FDA

Ritonavir, also called Kaletra, is approved by the FDA for 1 uses which include HIV .

HIV

Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with null

Effectiveness

How Kaletra Affects Patients

Ritonavir is a medication used to treat HIV-1. It works by blocking a part of HIV called protease, which is necessary for HIV to spread and cause infection. Ritonavir stops the spread of HIV by preventing the formation of infectious viral particles. It is usually taken in combination with other anti-HIV drugs and requires a low dose of ritonavir to increase its effectiveness.

How Kaletra works in the body

Ritonavir is used to fight HIV by blocking the enzyme that cuts up proteins needed by the virus to replicate. It also blocks the cytochrome P450 enzyme in the intestines and liver, which helps prevent other protease inhibitors from being transported or released from cells. This makes it harder for HIV to spread.

When to interrupt dosage

The proposed measure of Kaletra is contingent upon the diagnosed condition, including weight 40 kg or more, HIV (Human Immunodeficiency Virus) and Mild to Moderate COVID-19. The dosage shifts, based on the delivery procedure (e.g. Oral or Tablet, film coated - Oral) featured in the following table.

Condition

Dosage

Administration

COVID-19

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Hepatitis C, Chronic

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Hepatitis C, Chronic

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

HIV

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Obesity

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

SARS-CoV-2 Positive Patients

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Warnings

Kaletra has twenty-five contraindications, so it should not be taken while battling the conditions mentioned in the following table.

Kaletra Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulmonary Arterial Hypertension

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Kaletra.

Common Kaletra Drug Interactions

Drug Name

Risk Level

Description

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Ritonavir.

Alfuzosin

Major

The serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.

Amiodarone

Major

The metabolism of Amiodarone can be decreased when combined with Ritonavir.

Amodiaquine

Major

The metabolism of Amodiaquine can be decreased when combined with Ritonavir.

Anagrelide

Major

The metabolism of Anagrelide can be increased when combined with Ritonavir.

Kaletra Toxicity & Overdose Risk

There is little known about the effects of ritonavir overdose in humans, though one patient experienced tingling sensations after taking 1500 mg per day for two days. One post-marketing case has been reported of kidney failure and an allergy-like reaction. Rat tests suggest that it would take more than 2500 mg/kg to be lethal, and that other side effects could include liver damage, inflammation of the pancreas, or an allergic reaction.

image of a doctor in a lab doing drug, clinical research

Kaletra Novel Uses: Which Conditions Have a Clinical Trial Featuring Kaletra?

43 active trials are currently being conducted to assess the potential of Kaletra in alleviating Chronic hepatitis C genotype 1a, weight 40 kg or more and HIV (Human Immunodeficiency Virus) symptoms.

Condition

Clinical Trials

Trial Phases

COVID-19

0 Actively Recruiting

Obesity

0 Actively Recruiting

HIV

39 Actively Recruiting

Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4

Hepatitis C, Chronic

0 Actively Recruiting

Hepatitis C, Chronic

0 Actively Recruiting

SARS-CoV-2 Positive Patients

0 Actively Recruiting

Kaletra Reviews: What are patients saying about Kaletra?

5

Patient Review

4/14/2008

Kaletra for HIV

While I don't know for certain if Kaletra played a role, I now have necrosis in both of my hips. Additionally, it has made me gain weight and makes losing weight much more difficult.

5

Patient Review

9/20/2010

Kaletra for HIV

Anesthesia can have a variety of potential side effects, including nausea, vomiting, dizziness, and drowsiness. More serious risks include heart problems, breathing difficulties, and allergic reactions. Be sure to discuss all the possible risks and benefits of anesthesia with your doctor before having any procedure done.

5

Patient Review

2/21/2009

Kaletra for HIV

I was on Kaletra and Truvada for six years with few problems other than gastrointestinal issues. Recently, my cholesterol started to rise slowly, so my doctor switched me to Reyataz/Norvir/Truvada.

5

Patient Review

12/24/2009

Kaletra for HIV

Kaletra/Combivar has been working great for me for the last 5 years. I've never had any issues and it's kept me undetectable this whole time.

5

Patient Review

6/24/2014

Kaletra for Prevention of HIV Infection after Exposure

I experienced no negative side effects from this drug, which is great. It can be taken with or without food, and it seems to work best when taken with other anti-HIV medications.

4.7

Patient Review

4/28/2010

Kaletra for HIV

I've been undetectable since 2000, thanks to this drug in combination with Sustiva and Viread. I used to take Combivor but had to switch because it caused muscle depletion (I can't remember the medical term for it). The other reviewer is right - the cost of this medication is outrageous. I have Medicare D insurance and the copay is through the roof.

4.7

Patient Review

1/2/2016

Kaletra for HIV

I had a lot of bad side effects when I first started taking Atripla, but then my doctor put me on Kaletra and I haven't had any problems since.

4.7

Patient Review

10/28/2007

Kaletra for HIV

4.3

Patient Review

12/7/2007

Kaletra for HIV

I experienced some nausea when I first started taking this medication, but it quickly subsided. Additionally, this drug worked when others have failed in the past. I've been taking it for over two years now without any issues of resistance.

4.3

Patient Review

5/17/2013

Kaletra for HIV

Kaletra in conjunction with Truvada seems to help control some of the gastric issues I experience. However, I wish it had more of an impact on my CD4 count.

4

Patient Review

10/27/2008

Kaletra for HIV

My only issue is the expense. With everything rising, I struggle to pay my copay. Is there any assistance?

4

Patient Review

12/14/2011

Kaletra for HIV

I've been taking Kaletra, Viread, and Ziagen for five years now with few problems. The biggest issue has been high cholesterol from Kaletra, but I take Pravastatin to help with that. The four pills are large but manageable. My CD4 counts have stayed undetectable and incredible for over five years without any nausea from Kaletra.

3.7

Patient Review

10/23/2007

Kaletra for HIV

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kaletra

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there a generic for Kaletra?

"Kaletra is a combination of two medications, lopinavir and ritonavir, that is FDA approved for the treatment of HIV-1 infection in adult and pediatric patients. The generic formulations of Kaletra are being manufactured by Lannett and Camber Pharmaceuticals."

Answered by AI

What are the side effects of Kaletra?

"The following effects may occur: diarrhea, nausea, vomiting, stomach upset, gas, headache, and trouble sleeping. If you experience any of these effects for an extended period of time, or if they worsen, tell your doctor or pharmacist. Keep in mind that your doctor prescribed this medication because they believe that the benefits of taking it outweigh the potential risks of side effects."

Answered by AI

What is Kaletra prescribed for?

"KALETRA can decrease the amount of HIV in your blood and increase your CD4+ cell counts.

A prescription medicine, KALETRA is taken with other antiretroviral medicines to treat human immunodeficiency virus-1 (HIV-1) infection in adults and children aged 14 days or older. HIV is the virus that causes AIDS (acquired immune deficiency syndrome). KALETRA works by decreasing the amount of HIV in your blood and increasing CD4+ cell counts."

Answered by AI

Clinical Trials for Kaletra

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Erin P Finley, PhD MPH

Image of Brigham and Womens Hospital in Boston, United States.

Chia Seeds for Breastfeeding

18 - 45
All Sexes
Boston, MA

The investigators' over-arching hypothesis is that mechanical and compositional properties of chia seeds supplemented during lactation diminish obesity-induced intestinal inflammation and barrier dysfunction. The investigators hypothesize these changes will result in: 1) reduced maternal systemic inflammation (serum CRP and IL-6) and increased gut microbial diversity and richness, 2) reduced HM fat and inflammatory markers, metrics the research team have demonstrated differ in tandem with maternal metabolic health and 3) improved infant growth/body composition. To test these hypotheses, investigators will evaluate chia seed supplementation during lactation in a 6wk multi-site pilot RCT (Aim 1) and through translational studies using human enteroids (Aim 2).

Waitlist Available
Has No Placebo

Brigham and Womens Hospital (+1 Sites)

David A Fields, Phd

Have you considered Kaletra clinical trials?

We made a collection of clinical trials featuring Kaletra, we think they might fit your search criteria.
Go to Trials
Image of Public Health Research Center: Clinical Exercise Research Center in Columbia, United States.

Pistachio Snacking for Obesity

25 - 45
All Sexes
Columbia, SC

The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults. Secondary goals include evaluating effects on changes in diet quality, sleep characteristics, physical activity, and hormonal health in women. In randomized order, participants will complete four days of pistachio snacking and four days of normal dietary habits (control). For both conditions, primary outcomes of resting substrate metabolism, metabolic flexibility during exercise, and post-exercise substrate metabolism will be measured pre-post intervention via indirect calorimetry. Secondary outcome of diet quality (kcal, carb, fat, protein) will be measured pre-post intervention via diet log. Exploratory outcomes of daily physical activity (steps, intensity), nightly sleep characteristics (quantity, quality, latency, efficiency), and daytime sleepiness and hunger.

Recruiting
Has No Placebo

Public Health Research Center: Clinical Exercise Research Center

Katie R Hirsch, PhD

Image of People Science in Los Angeles, United States.

CLB101 for Gut Health in Obesity

18 - 65
All Sexes
Los Angeles, CA

Anaerostipes caccae CLB101TM️ is a next-generation probiotic isolated from healthy humans. It was shown to be in decreased abundance in people with protein-based food sensitivities/allergies. CLB101TM️ is different from most commercially available probiotics in that it directly produces butyrate. Butyrate is a naturally occurring small molecule found in the gut of healthy individuals, and it has been shown to provide clinical benefits including strengthening the gut lining, providing immune health, and supporting a balanced microbiome. The rationale for developing CLB101TM️ is to provide a probiotic that generates butyrate in the targeted intestinal locations where it can optimally benefit cells that line the gut.

Waitlist Available
Paid Trial

People Science

Naoh Craft, MD

ClostraBio Inc.

Have you considered Kaletra clinical trials?

We made a collection of clinical trials featuring Kaletra, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Local Restaurant Site in Bryan, United States.

Menu Labeling for Healthy Habits and Diet

18+
All Sexes
Bryan, TX

This study evaluates the impact of culturally tailored menu labeling interventions on psychosocial factors and ordering behavior among customers in two independently owned Hispanic restaurants in East-Central Texas. Participants will be exposed to one of three sequential menu conditions at each restaurant: (1) a standard menu without nutrition information, (2) a paper menu with bilingual nutrition labels, or (3) a digital menu app enhanced with Augmented Reality (AR) and Artificial Intelligence (AI) providing interactive nutrition guidance. The study will assess whether menu formats influence nutrition literacy, decision-making confidence, self-efficacy, attitudes, behavioral intentions, and actual ordering behavior. Data will be collected through surveys, purchase receipts, and app interaction logs.

Recruiting
Has No Placebo

Local Restaurant Site

Hyunjung Lee, PhD

Have you considered Kaletra clinical trials?

We made a collection of clinical trials featuring Kaletra, we think they might fit your search criteria.
Go to Trials